Dolan Arthritis

The GO SAVE  Study is a Clinical Research study testing a medication called Golimumab. Although already approved for the treatment of moderate to severe RA, the GO SAVE study is designed to further examine the effectiveness of Golimumab in reducing pain and maintain movement in joints in patients with RA. You may be eligible to participate if you; Are 18 years or older Have received at least 3 months of treatment with one of the TNF-alpha blocking agents etanercept or adalimumab, in combination with methotrexate. Are no getting adequate ... Read More

Are you one of 5 Million individuals living with Lupus? If you are, we invite you to consider participating in the ILLUMINATE Research Study Program. The program is evaluating a new investigational medication for systemic lupus erythematosus (SLE), the most common form of lupus. We are one of many sites across the country taking part in this research If you or someone you know: Is 18 years of age or older and Have been diagnosed with SLE This research study may be an option for you. To determine if you may qualify to take part, our doctors ... Read More

Do you have Rheumatoid arthritis? Are you taking rheumatoid arthritis medication but still have painful, stiff and swollen joints? If the answer to these questions is yes, and you are 18 years of age or older, you may be eligible to participate in a clinical research program evaluating a new investigational medication for rheumatoid arthritis. Please contact our Research Department to inquire about this ... Read More

Age 18 and older, with active RA. Are not currently on, methotrexate therapy. To be eligible participants must not be taking, or have previously taken, methotrexate. If you would like additional information on these trials, Please contact our Srudy Coordinator Dawn Bynum at 562-243-8199 or by email at dolanresearch@yahoo.com You may also visit www.researchra.com to take an online survey to see if you may qualify for the above referenced trials. Choosing to participate in a clinical trial is an important personal decision, to learn more about ... Read More

Age 18 and older, with active RA. Experienced inadequate clinical response or who have been unable to tolerate standard RA therapies. To be eligible, potential participants must have tried and not responded to or been able to tolerate etanercept (Enbrel), infliximab (Remicade), or adalimumab (Humira) therapy for a particular length of time (specified during screening). If you would like additional information on these trials, Please contact our Srudy Coordinator Dawn Bynum at 562-243-8199 or by email at dolanresearch@yahoo.com You may also ... Read More